News >

Predictive, Prognostic Biomarkers Continue to Enhance Treatment Decisions in NSCLC

Jessica Hergert
Published: Wednesday, Nov 13, 2019

Isabel Preeshagul, DO, MBS, medical oncologist at Memorial Sloan Kettering Cancer Center

Isabel Preeshagul, DO, MBS

Predictive and prognostic biomarkers have revolutionized the treatment decision process for patients with non–small cell lung cancer (NSCLC), said Isabel Preeshagul, DO, MBS, and researchers are now seeking to even further enhance this precision medicine process.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication